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Abstract: 1 
High plasma choline has been associated with the metabolic syndrome and risk of chronic 2 
diseases, including cardiovascular disease. However, dietary choline is not correlated with 3 
choline plasma concentrations, and there are few studies and contradictory evidence regarding 4 
dietary choline and cardiovascular events. In addition, a recommended dietary allowance for 5 
choline has not been established and remains a point of contention.  6 
This study assessed the association between dietary choline, including choline forms, and risk 7 
of incident acute myocardial infarction (AMI) in patients with suspected stable angina pectoris 8 
(SAP). 9 
In total 1981 patients (80% men, median age 62) from the Western Norway B Vitamin 10 
Intervention Trial were included in this analysis. Information on dietary choline was obtained 11 
using a 169-item food frequency questionnaire. The Cardiovascular Disease in Norway project 12 
provided data on AMI. Risk associations were estimated using Cox-regression analysis using 13 
energy-adjusted choline intake. 14 
Median (25th, 75th percentile) total energy-adjusted choline intake was 288 (255, 326) mg/d. 15 
During a median (25th, 75th percentile) follow-up of 7.5 (6.3, 8.8) years, 312 (15.7%) patients 16 
experienced at least one AMI. Increased intakes of energy-adjusted choline (HR [95% CI] per 17 
50 mg increase 1.11 [1.03, 1.20]), phosphatidylcholine (HR per 50 mg increase 1.24 [1.08, 18 
1.42]) and sphingomyelin (HR per 5 mg increase 1.16 [1.02, 1.31]) were associated with higher 19 
AMI risk.  20 
Higher dietary intakes of total choline, phosphatidylcholine and sphingomyelin were associated 21 
with increased risk of AMI in patients with SAP. Future studies are necessary to explore 22 
underlying mechanisms for this observation. 23 
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1. Introduction 26 
Choline is an essential nutrient, which to some extent can also be formed endogenously in the 27 
liver. Choline appears in both water- and lipid-soluble forms in both body and diet. Water-28 
soluble forms include free choline, phosphocholine and glycerophosphocholine. They enter the 29 
liver via the portal circulation after intestinal choline transporter-mediated absorption [1,2]. 30 
Lipid-soluble forms include phosphatidylcholine (PC) and sphingomyelin (SM). PC is 31 
hydrolyzed by phospholipase A2 to lysoPC prior to absorption in the enterocyte [1,2]. LysoPC 32 
can be either reacetylated to PC or further broken down to glycerophosphocholine, and finally 33 
free choline [1,3]. PC enters the bloodstream through the lymphatic system incorporated in 34 
chylomicrons, thereby being delivered directly to peripheral tissue (muscle and adipose) before 35 
reaching the liver [1]. SM is hydrolyzed by small intestinal brush border enzymes to ceramids 36 
and phosphocholine, and the latter is degraded to choline and transported by the portal vein to 37 
the liver [3]. Chemical structures of choline forms are provided in supplementary figure 1.  38 
The majority of choline in both diet and body is in the form of PC. Absorbed free choline is 39 
mainly used for PC formation via the Kennedy pathway, which is in its turn secreted into bile 40 
and very-low density lipoproteins (VLDL) [1,4]. The amount of PC in the bile largely exceeds 41 
the dietary supply (respectively 11 g/day vs 1-5 g/day). Approximately 95% of biliary PC is 42 
reabsorbed and 40% is returned to the liver, implying an extensive enterohepatic choline cycle 43 
[2]. Endogenous PC formation occurs via the phosphatidylethanolamine N-methyltransferase 44 
pathway, where PC is formed from phosphatidylethanolamine [1,2,4].  45 
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Supplementary figure 1: Chemical structures of choline and choline forms. Adapted from 
Patterson et al. [5]. 
Dietary sources of choline are foods of animal origin like eggs, pork, beef, liver, milk, and plant 46 
sources like soybean and wheat germ [6]. Consumption of choline forms is dependent on the 47 
individual dietary pattern [1,2,7]. Unfortunately, data on choline content is not included in most 48 
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food composition databases, including the Norwegian one [8]. There is no consensus so far on 49 
dietary choline requirements. While in the US the adequate intake is set to 550 mg/d for men 50 
and 425 mg/d for women, based on a few studies involving mostly men [9], values set in the 51 
European Union are slightly lower [10]. No reference values have been published specifically 52 
for the Nordic countries [11]. Mean choline intake in mainly North American and European 53 
countries, was below the dietary recommendation [12]. It is however not possible to conclude 54 
on the prevalence of choline intake deficiency since only an adequate intake has been 55 
established so far [12]. Additionally, few studies have reported intake of the individual choline 56 
forms [1,12], indicating the importance of evaluating choline intake in the population. 57 
Choline is crucial for the synthesis of acetylcholine and major membrane phospholipids. Higher 58 
plasma choline has been associated with increased risk of cardiovascular disease (CVD) 59 
[4,9,13]. Choline’s oxidation product, betaine, links choline to the one-carbon metabolism via 60 
its role in the betaine-homocysteine methyltransferase reaction where a methylgroup from 61 
betaine is transferred to homocysteine, forming methionine and dimethylglycine (DMG) [9,14]. 62 
Elevated plasma total homocysteine (tHcy) has been linked to increased risk of coronary artery 63 
disease (CAD) [15] and plasma DMG levels have been associated with risk of future acute 64 
myocardial infarction (AMI) [14] in the current population.  65 
Only few and contradictory findings are published on dietary choline intake and CVD risk 66 
[13,16]. Additionally, previous studies have reported either no [6] or only marginal [13,17] 67 
correlations between plasma choline levels and dietary choline intake. So far, only egg intake 68 
has been linked to plasma choline levels in several studies [6,18]. In light of the few existing 69 
studies [16], it was the aim of this study to investigate the association between dietary choline, 70 
including choline forms, and subsequent risk of AMI in patients with stable angina pectoris 71 
(SAP). 72 
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2. Patients and methods 73 
2.1 Study cohort 74 
In total 3090 adult patients, undergoing elective coronary angiography due to suspected CAD 75 
between 1999 and 2004 at Haukeland University Hospital, Bergen and Stavanger University 76 
Hospital, Stavanger in Norway were enrolled in the Western Norway B-Vitamin Intervention 77 
Trial (WENBIT, NCT00354081). This was a prospective, randomized, double-blind, placebo-78 
controlled secondary prevention study that investigated the effect of vitamin B treatment on 79 
mortality and cardiovascular outcomes [19]. The study protocol has been described elsewhere 80 
[19]. For the current analysis, we included only patients with suspected SAP (n = 2573). We 81 
excluded patients with missing dietary data, including choline intake (n = 565), and those which 82 
reported extreme energy intake (i.e. <3000 kJ or >15 000 kJ for women and <3300 kJ or 83 
>17 500 kJ for men) (n = 27), which resulted in 1981 patients eligible for analyses.  84 
The study was carried out according to the Declaration of Helsinki and approved by the 85 
Norwegian Data Inspectorate and the Regional Committee for Medical Health Research Ethics. 86 
All participants provided written informed consent. 87 
2.2 Baseline data 88 
Clinical information on patients’ lifestyle and medical history was obtained from self-89 
administered questionnaires or through interviews and verified by hospital records. Participants 90 
were defined as smokers based on self-reported smoking habits and serum cotinine levels >85 91 
nmol/L at baseline [14]. Diabetes mellitus was defined according to preexisting diagnosis, 92 
HbA1c >6.5%, fasting blood glucose  ≥7 mmol/L or non-fasting blood glucose  ≥11.1 mmol/L 93 
according to the World Health Organization guidelines [20].  94 
2.3 Follow-up and study end points 95 
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The primary end point of this study was incident AMI, including fatal and nonfatal events, 96 
classified according to the revised definition of AMI criteria (ICD-10 codes I21, I22, I46.1, 97 
R96, R98) [21]. Information on study outcomes was obtained from the Cardiovascular Disease 98 
in Norway (CVDNOR; https://cvdnor.b.uib.no) project, which reported on patients being 99 
discharged with a CVD diagnosis between 1994 and 2009 from 42 Norwegian public hospitals, 100 
and from the Cause of Death Registry at Statistics Norway (http://www.ssb.no). 101 
2.4 Dietary assessment 102 
Dietary data was obtained from a food frequency questionnaire (FFQ) given at the first visit 103 
and returned by email to the study center or at the one-month follow-up visit. The FFQ was an 104 
adaptation of a 180-item FFQ from 1992 developed at the Department of Nutrition, University 105 
of Oslo and designed to assess the habitual food intake of Norwegian adults. The adaptation 106 
resulted in a 169-food item FFQ designed to obtain information on the usual food intake over 107 
the past year. The frequency of consumption was given per day, week, month or never 108 
consumed depending on the food item. Portion sizes were given as household measures or units 109 
such as slices or pieces. Questions on the use of vitamin or mineral supplements were included, 110 
however, there were no questions regarding choline supplementation. 111 
Nutrient intake was calculated using a database and software system developed at the 112 
Department of Nutrition, University of Oslo (Kostberegningssystem, version 3.2, University of 113 
Oslo, Norway). Intake of choline and individual choline forms was quantified using the U.S. 114 
Department of Agriculture (USDA) Database for Choline Content of Common Foods, release 115 
2 [5]. Total dietary choline intake was estimated as the sum of free choline, PC, SM, 116 
phosphocholine and glycerophosphocholine. Choline content for food items that did not occur 117 
in the USDA database was estimated using nutritionally equivalent foods. For dishes that did 118 
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not occur in the USDA database, choline content was calculated for each ingredient in the FFQ 119 
recipe.  120 
2.5 Biochemical analyses 121 
Routine biochemical analyses were conducted at the laboratories in the recruiting hospitals, 122 
whereas study-specific analyses were conducted by Bevital AS, Bergen, Norway 123 
(http://www.bevital.no). Choline compounds in plasma were analyzed by liquid 124 
chromatography-tandem mass spectrometry [22]. Details on the collection, storage and 125 
biochemical analysis of samples have been described previously [14]. 126 
2.6 Statistical analyses 127 
Baseline variables and dietary intake are reported as median (25th, 75th percentile) for 128 
continuous variables or counts (percentages) for categorical variables. Patient baseline 129 
characteristics and dietary intake across quartiles of energy-adjusted choline intake were 130 
compared by median linear or logistic regression for continuous and categorical variables 131 
respectively. To adjust for reported energy intake the residual method was used for choline 132 
intake and nutrient density was calculated for macronutrients, food groups and specific food 133 
items [23]. 134 
Kaplan-Meier plots were used to visualize differences in survival across the quartiles of total 135 
choline intake, assessed by the log-rank test. Cox regression models were used to estimate the 136 
association between total choline intake and intake of choline forms and risk of AMI. The 137 
hazard ratios (HRs) and 95% confidence intervals (CI) were reported per daily increment of 50 138 
mg for total choline and PC and of 5 mg for the remaining choline forms. The first model 139 
included reported energy intake, the second model additionally included age and sex and the 140 
final model additionally included smoking status. Traditional risk factors for CAD, fasting 141 
status, statin use and study intervention were not included in the model since they were not 142 
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associated with choline intake and thus not considered being a confounder. Generalized additive 143 
models (GAMs) were plotted for the association between intakes of total choline and choline 144 
forms as continuous variables with AMI risk to explore non-linear relationships.  145 
Effect modifications were studied according to subgroups of traditional risk factors for CAD, 146 
such as age, sex, body mass index, hypertension, smoking, diabetes mellitus, estimated 147 
glomerular filtration rate, baseline serum lipid parameters (including low-density lipoprotein 148 
cholesterol, high-density lipoprotein cholesterol, apolipoprotein B (apoB) and apoA1) and to 149 
statin use at discharge and prior AMI. Continuous variables were dichotomized according to 150 
their median value and interactions were tested by adding interaction product terms with the 151 
continuous variable to the final cox regression model.    152 
Statistical analyses were performed using R version 3.4.3 (The R Foundation for Statistical 153 
Computing, Vienna, Austria), and the packages within the “tidyverse” (“dplyr”, “ggplot2”, 154 
“tidy”, “broom”, “purrr”, “forcats”, “tidyr”) [24], “survival” [25] and “forestplot” [26] was 155 
used for statistical analyses. 156 
3. Results 157 
3.1 Baseline characteristics 158 
Baseline characteristics of the study patients (n = 1981) according to quartiles of energy-159 
adjusted choline intake are presented in Table 1. The cohort consisted of 80% men, and the 160 
median (25th, 75th percentile) age was 62 (55, 69) years. In the total population, 28% were 161 
current smokers, 47% were diagnosed with hypertension, 31% had diabetes mellitus and 44% 162 
had a history of AMI. Moreover, choline intake was slightly inversely associated with plasma 163 
betaine, DMG and tHcy, as well as with plasma trimethylamine N-oxide (TMAO), but not 164 
associated with plasma concentrations of other one-carbon metabolites. A positive association 165 
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was shown with plasma riboflavin, pyridoxal-5’-phosphate (PLP), and serum cobalamin and 166 
folate, whereas no association was observed with plasma methylmalonic acid (MMA).  167 
TABLE 1 
Patient characteristics according to quartiles of energy-adjusted daily choline intake 
Variable Total cohort Q1  (≤254) Q2  (255 - 288) Q3 (288 - 326) Q4 (>326) P trend 
 
(n = 1981) (n = 496) (n = 495) (n = 495) (n = 495) 
 
Total choline, mg/d 288 (255, 326) 232 (212, 244) 273 (264, 280) 306 (297, 315) 361 (341, 397) <0.001 
Incident AMI, n (%) 312 (15.7) 57 (11.5) 87 (17.6) 78 (15.8) 90 (18.2) 0.007 
Age, y 62 (55, 69) 62 (55, 68) 63 (56, 70) 62 (55, 70) 61 (55, 67) 0.036 
Male sex, n (%) 1588 (80.2) 429 (86.5) 375 (75.8) 384 (77.6) 400 (80.8) <0.001 
BMI, kg/m2 26 (24, 28) 25 (23, 28) 26 (24, 28) 26 (24, 28) 26 (25, 29) <0.001 
Cardiovascular risk factors, n (%) 
 
Smokers 558 (28.2) 125 (25.2) 123 (24.8) 131 (26.5) 179 (36.2) 0.913 
 
Hypertension 938 (47.3) 217 (43.8) 232 (46.9) 237 (47.9) 252 (50.9) 0.324 
 
Diabetes mellitus 613 (30.9) 138 (27.8) 146 (29.5) 145 (29.3) 184 (37.2) 0.504 
Cardiovascular history, n (%) 
 
Prior AMI 864 (43.6) 214 (43.1) 212 (42.8) 207 (41.8) 231 (46.7) 0.92 
 
Prior CABG 285 (14.4) 73 (14.7) 70 (14.1) 65 (13.1) 77 (15.6) 0.796 
 
Prior PCI 450 (22.7) 130 (26.2) 95 (19.2) 110 (22.2) 115 (23.2) 0.009 
Medication use, n1 (%) 
 Statins 1769 (89.3) 442 (89.1) 436 (88.1) 445 (89.9) 446 (90.1) 0.609 
 ACE inhibitors 395 (19.9) 85 (17.1) 96 (19.4) 101 (20.4) 113 (22.8) 0.358 
 ARB 230 (11.6) 45 (9.1) 58 (11.7) 63 (12.7) 64 (12.9) 0.174 
 Aspirin 1784 (90.1) 464 (93.5) 446 (90.1) 434 (87.7) 440 (88.9) 0.049 
 β-Blockers 1533 (77.4) 395 (79.6) 378 (76.4) 383 (77.4) 377 (76.2) 0.214 
 Diuretics 181 (9.1) 34 (6.9) 48 (9.7) 55 (11.1) 44 (8.9) 0.106 
CRP, mg/L 1.7 (0.8, 3.3) 1.7 (0.9, 3.2) 1.5 (0.7, 3.1) 1.5 (0.8, 3.1) 1.8 (0.9, 3.7) 0.977 
eGFR, mL/min/1.73m2 92 (82, 100) 92 (83, 100) 91 (80, 98) 92 (81, 100) 94 (83, 101) 0.059 
Plasma levels of one-carbon metabolites, µmol/L 
 
Choline 9.5 (8.1, 11.2) 9.6 (8.2, 11.2) 9.5 (8.0, 11.2) 9.4 (8.1, 11.2) 9.4 (8.1, 11.4) 0.876 
 
Betaine 39.2 (32.1, 48.0) 40.2 (33.4, 48.9) 39.3 (30.9, 46.8) 39.3 (33.1, 48.4) 38.2 (31.3, 46.7) 0.023 
 
DMG 4.0 (3.3, 4.8) 4.1 (3.4, 4.9) 4.0 (3.2, 4.7) 4.0 (3.3, 5.0) 3.8 (3.2, 4.8) 0.001 
 Glycine 198 (175, 229) 203 (180, 237) 199 (175, 232) 199 (176, 229) 193 (169, 223) 0.001 
 Serine 94 (81, 107) 95 (82, 108) 94 (80, 109) 95 (83, 107) 92 (81, 105) 0.354 
 Methionine 26.6 (22.7, 32.2) 26.6 (22.9, 31.1) 26.2 (22.5, 31.9) 26.5 (22.5, 32.0) 27.3 (22.8, 33.3) 0.177 
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 3.2 Dietary choline intake 168 
Dietary intake of choline and choline species, as well as nutrients and food groups across 169 
quartiles of energy-adjusted choline intake is shown in Table 2. The median (25th, 75th 170 
percentile) total energy intake was 2036 (1657, 2483) kcal/d and the energy-adjusted total 171 
choline intake was 288 (255, 326) mg/d. Total choline intake was mainly derived from PC (123 172 
mg, 43%), followed by free choline (74 mg, 26%), glycerophosphocholine (63 mg, 22%), SM 173 
 
Total homocysteine 10.2 (8.6, 12.1) 10.4 (8.9, 12.7) 10.2 (8.5, 12.0) 10.2 (8.6, 12.1) 9.9 (8.5, 11.6) 0.004 
 
Cystathionine 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 0.2 (0.2, 0.4) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 0.860 
 Cysteine 286 (265, 308) 286 (264, 307) 286 (264, 309) 286 (266, 309) 287 (266, 308) 0.681 
TMAO,  µmol/L 5.7 (3.6, 9.4) 5.3 (3.5, 8.5) 5.6 (3.6, 8.2) 5.8 (3.9, 9.9) 6.1 (3.8, 10.9) 0.004 
TML,  µmol/L 0.7 (0.5, 0.9) 0.7 (0.5, 0.8) 0.7 (0.5, 0.9) 0.7 (0.5, 0.9) 0.7 (0.5, 0.9) 0.132 
Plasma markers of B-vitamin status 
 Riboflavin, nmol/L 11.1 (7.6, 17.5) 9.6 (6.6, 15.6) 11.2 (7.8, 17.6) 11.1 (7.8, 16.9) 12.2 (8.3, 19.1) 0.282 
 PLP, nmol/L 40.8 (29.6, 56.5) 37.9 (27.2, 51.9) 41.6 (29.6, 56.1) 40.4 (29.8, 56.4) 43.4 (32.5, 61.6) 0.001 
 Cobalamin, pmol/L 340 (260, 428) 317 (239, 399) 338 (259, 433) 344 (259, 435) 365 (286, 449) 0.042 
 Folate, nmol/L 10.0 (7.3, 14.4) 9.5 (7.0, 12.7) 9.7 (7.0, 13.9) 10.1 (7.6, 15.6) 10.8 (7.8, 15.4) 0.034 
 MMA, µmol/L 0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.2 (0.1, 0.2) 0.158 
Serum lipids, mmol/L 
 
Total cholesterol,  4.9 (4.2, 5.6) 4.8 (4.2, 5.5) 4.9 (4.2, 5.6) 4.8 (4.2, 5.7) 5.0 (4.3, 5.7) 0.496 
 
LDL cholesterol,  2.9 (2.3, 3.6) 2.9 (2.3, 3.6) 2.9 (2.4, 3.5) 2.8 (2.3, 3.6) 2.9 (2.4, 3.7) 0.747 
 
HDL cholesterol,  1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 1.2 (1.0, 1.5) 1.2 (1.0, 1.4) 1.2 (1.0, 1.4) 0.175 
 
TG,  1.54 (1.1, 2.2) 1.6 (1.1, 2.2) 1.5 (1.1, 2.2) 1.5 (1.1, 2.1) 1.5 (1.1, 2.3) 0.529 
 
ApoB, g/L 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 0.8 (0.7, 1.0) 0.9 (0.7, 1.0) 0.423 
 
ApoA1, g/L 1.3 (1.1, 1.4) 1.3 (1.1, 1.4) 1.3 (1.1, 1.4) 1.2 (1.1, 1.4) 1.3 (1.1, 1.4) 0.837 
Continuous variables are presented as medians (25th,75th percentile) and categorical variables are reported as counts (%). Patient 
baseline characteristics across quartiles are compared by median linear (continuous variables) or logistic (categorical variables) 
regression. Dietary choline intake is energy-adjusted according to the residual method. 
1 At discharge from hospital. 
ARB indicates angiotensin II receptor blockers; AMI, acute myocardial infarction; ApoA1, apolipoprotein A1; ApoB, 
apolipoprotein B; CABG, coronary artery bypass grafting; CRP, C-reactive protein; DMG, dimethylglycine; eGFR, estimated 
glomerular filtration rate; MMA, methylmalonic acid; PCI, percutaneous coronary intervention; PLP, pyridoxal phosphate; TG, 
triglycerides; TMAO, trimethylamine N-oxide; TML, trimethyllysine. 
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and phosphocholine (both 13 mg, 5%). Higher intake of total choline was inversely associated 174 
with intake of carbohydrates and positively associated with intake of fiber and protein. There 175 
was a slight increase in total fat, a decrease in saturated fatty acids (SFAs) and no change in 176 
intake of monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs) with 177 
increasing choline intake. Further, positive associations were found with intakes of cholesterol, 178 
alcohol, fruits and berries and vegetables. As expected, main dietary choline sources such as 179 
meat, fish, eggs and milk were all positively associated with choline intake.  180 
 
TABLE 2 
 Daily dietary intake according to quartiles of energy-adjusted choline intake 
 
Total cohort Q1 (≤254) Q2 (255 - 288) Q3 (288 - 326) Q4 (>326) P trend 
 
(n = 1981) (n = 496) (n = 495) (n = 495) (n = 495) 
 
Total choline, 
mg/day 
288 (255, 326) 232 (212, 244) 273 (264, 280) 306 (297, 315) 361 (341, 397) <0.001 
Choline forms, mg/d 
 Free choline 74 (66, 85) 63 (56, 70) 72 (67, 78) 77 (71, 84) 89 (80, 104) <0.001 
 PC 123 (103, 147) 97 (84, 110) 117 (104, 128) 134 (117, 151) 159 (137, 183) <0.001 
 SM 13 (11, 15) 10 (9, 12) 12 (11, 14) 14 (12, 15) 16 (14, 19) <0.001 
 Phosphocholin
e 
13 (10, 16) 9 (7, 11) 12 (10, 14) 14 (11, 17) 17 (14, 21) <0.001 
 Glycerophosph
ocholine 
63 (49, 78) 46 (36, 56) 61 (50, 70) 68 (57, 79) 86 (69, 105) <0.001 
Betaine, mg 135 (105, 169) 144 (116, 180) 127 (99, 159) 133 (102, 166) 135 (108, 169) <0.001 
Energy, kcal 2036  
(1657, 2483) 
2173  
(1809, 2604) 
1903  
(1547, 2345) 
1963  
(1581, 2385) 
2093  
(1692, 2564) 
<0.001 
Carbohydrates, 
E% 
49.8  
(45.5, 54.0) 
51.4  
(46.9, 55.3) 
50.7  
(47.4, 54.6) 
49.6  
(45.2, 53.5) 
47.8  
(43.3, 52.2) 
<0.001 
 Fiber, 
g/1000kcal 
11.9  
(10.0, 14.0) 
11.4  
(9.7, 13.0) 
12.1  
(10.2, 14.3) 
11.9  
(10.2, 14.2) 
12.2  
(9.9, 14.8) 
<0.001 
Protein, E% 16.7  
(15.2, 18.4) 
15.1  
(13.9, 16.6) 
16.3  
(15.2, 17.8) 
17.1  
(15.8, 18.6) 
18.4  
(17.1, 20.0) 
<0.001 
Total fat, E% 31.2  
(27.8, 35.0) 
31.9  
(28.4, 35.6) 
30.7  
(27.7, 34.5) 
31.2  
(27.9, 35.0) 
31.1  
(27.4, 34.7) 
0.035 
15 
 
 
SFA, E% 11.6  
(10.0, 13.3) 
12.1  
(10.4, 13.8) 
11.5  
(10.1, 13.0) 
11.5  
(10.0, 13.2) 
11.3  
( 9.6, 13.1) 
<0.001 
 
MUFA, E% 10.2 (9.0, 11.6) 10.2 (9.0, 11.6) 10.1 (8.9, 11.4) 10.4 (8.9, 11.7) 10.3 (9.0, 11.6) 0.208 
 
PUFA, E% 6.9 (5.8, 8.4) 6.9 (5.9, 8.6) 6.6 (5.6, 8.2) 6.9 (5.9, 8.2) 7.1 (5.7, 8.4) 0.016 
Cholesterol, mg 278 (216, 359) 257 (195, 324) 255 (197, 327) 285 (217, 356) 338 (261, 420) <0.001 
Alcohol, E% 1.0 (0.0, 2.8) 0.5 (0.0, 2.2) 0.9 (0.0, 2.3) 1.2 (0.1, 2.9) 1.4 (0.2, 3.7) <0.001 
       
Meat, g/1000kcal 53.3  
(39.0, 68.9) 
49.6  
(35.9, 64.3) 
52.3  
(39.2, 67.8) 
54.5  
(40.2, 69.4) 
56.5  
(41.5, 73.0) 
<0.001 
Fish, g/1000kcal 48.7 
(33.6, 68.9) 
39.6 
(27.0, 58.6) 
47.7 
(33.8, 65.6) 
50.1 
(36.4, 67.9) 
59.9 
(42.0, 81.6) 
<0.001 
Eggs, g/1000kcal 7.2 (4.0, 11.2) 4.4 (2.6, 7.0) 6.7 (4.1, 10.0) 8.7 (5.2, 12.6) 10.4 (6.8, 15.3) <0.001 
Milk, g/1000kcal 117 (41, 193) 70 (21, 125) 112 (33, 179) 138 (68, 214) 170 (84, 249) <0.001 
Fruit and berries, 
g/1000kcal 
107.2  
(66.4, 161.7) 
98.3  
(61.8, 140.3) 
111.8  
(70.2, 165.6) 
110.4  
(69.4, 172.8) 
111.5  
(63.3, 169.4) 
0.005 
Vegetables, 
g/1000kcal 
88.8  
(57.5, 133.6) 
68.7  
(44.4, 98.4) 
87.8  
(58.4, 122.7) 
96.6  
(65.2, 146.5) 
116.5  
(72.5, 177.8) 
<0.001 
Corn products,  
g/ 1000kcal 
106.0  
(86.1, 127.2) 
116.9  
(95.7, 135.8) 
110.9  
(91.0, 129.2) 
104.1  
(86.9, 126.2) 
94.7  
(74.7, 114.6) 
<0.001 
Continuous variables are presented as medians (25th,75th percentile. Dietary intake across quartiles were compared by 
median linear regression. Choline and choline forms are energy-adjusted according to the residual method. The nutrient 
density method was used for other nutrients, food groups and specific food items. 
PC indicated phosphatidylcholine; SM, sphingomyelin. 
 
3.3 Dietary choline intake and risk of AMI 181 
During a median (25th, 75th percentile) follow-up time of 7.5 (6.3, 8.8) years, 312 (15.7%) 182 
patients experienced an AMI (table 1). Figure 1 depicts a Kaplan-Meier plot of event-free 183 
survival time across quartiles of energy-adjusted choline intake, showing a difference in event-184 
free survival between the quartiles, with better survival in the first quartile and similar survival 185 
in the other three quartiles.  186 
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Figure 1: Kaplan-Meier event-free survival curves for patients with choline intake in quartiles 
1 to 4. A non-parametric log-rank test was used to compare survival between quartiles of 
energy-adjusted choline intake. The x-axis is trimmed at 7.5 years.   
AMI indicates acute myocardial infarction. 
 In a cox-model adjusted for energy intake only, we observed increased risk for AMI per 50 188 
mg/d increment of total choline (HR 1.11, 95% CI [1.03, 1.20]) and PC (1.24 [1.08, 1.42]) 189 
intakes, and per 5 mg/d increment in SM (1.16 [1.02, 1.31]). These associations persisted after 190 
further adjustment for age and sex (model 2) and after additional adjustment for smoking 191 
(model 3) (Table 3). Intakes of free choline, phosphocholine or glycerophosphocholine intake 192 
were not associated with the risk of later AMI. Subgroup analyses showed no differences in 193 
AMI risk with regard to traditional risk factors for CAD (Supplementary figure 2). 194 
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The dose-response relationship between energy-adjusted choline intake and AMI is shown in 195 
Figure 2. A positive linear relationship was observed for total choline, PC and SM whereas for 196 
free choline, phosphocholine and glycerophosphocholine there was no relationship. 197 
TABLE 3 
Hazard ratios for incident AMI according to energy-adjusted choline intake from cox regression analysis  
 Model 11 Model 22 Model 33 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Total choline4 1.11 (1.03, 1.20) 0.006 1.12 (1.04, 1.21) 0.004 1.10 (1.02, 1.19) 0.015 
Free choline5 1.02 (0.99, 1.05) 0.280 1.02 (0.99, 1.06) 0.180 1.02 (0.98, 1.05) 0.341 
PC4 1.24 (1.08, 1.42) 0.002 1.25 (1.09, 1.44) 0.002 1.23 (1.07, 1.41) 0.003 
SM5 1.16 (1.02, 1.31) 0.019 1.17 (1.04, 1.32) 0.011 1.15 (1.03, 1.30) 0.017 
Phosphocholine5 1.06 (0.96, 1.18) 0.260 1.07 (0.96, 1.19) 0.203 1.07 (0.96, 1.19) 0.219 
Glycerophosphocholine5 1.01 (0.99, 1.03) 0.251 1.01 (0.99, 1.03) 0.249 1.01 (0.99, 1.03) 0.249 
1 Adjusted for energy intake 
2 Adjusted for energy intake, sex and age 
3 Adjusted for energy intake, sex, age and smoking 
4 per 50 mg per day increase 
5 per 5 mg per day increase 
HR indicates hazard ratio; CI, confidence interval; PC, phosphatidylcholine; SM, sphingomyelin. 
 198 
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Figure 2: Association of choline intake with risk of acute myocardial infarction using general 
additive models adjusted for total energy intake, sex, age and smoking. The solid lines show 
the observed association and the shaded areas 95% confidence intervals. Density plots 
indicate the distribution of dietary choline and choline forms. 
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Supplementary figure 2: Risk estimates per increment of 50 mg/d in total choline for incident 
AMI according to subgroups based on established risk factors for coronary artery disease 
based on a cox regression model adjusted for energy intake, sex, age and smoking. 
Continuous variables were dichotomized according to their median value and interactions 
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were tested statistically by adding interaction product terms with the non-dichotomized 
variable to the final cox model adjusted for total energy intake, sex, age and smoking. 
AMI indicates acute myocardial infarction; ApoA1, apolipoprotein A1; ApoB, apolipoprotein 
B; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio. 
4. Discussion 201 
It was the aim of this study to investigate the association of dietary total choline and choline 202 
forms on future AMI risk in patients with suspected SAP. In this study, higher dietary choline 203 
intake, more specifically total choline, PC and SM, was associated with increased AMI risk 204 
during long-term follow-up, and the associations appeared to be linear across the intake ranges. 205 
The intakes of free choline, phosphocholine and glycerophosphocholine did not seem to be 206 
associated with AMI risk.  207 
4.1 Previous studies on dietary choline and CVD risk 208 
A systematic review and meta-analysis of four prospective studies on dietary choline and risk 209 
of incident CVD (defined as CAD, stroke or total CVD) reported no association (risk ratio 1.00) 210 
between dietary total choline and risk of CVD [16]. The studies were, as opposed to the current 211 
investigation, performed in initially healthy populations, and no analysis of the individual 212 
dietary choline forms was provided [16]. The lack of analyses of choline in food items may be 213 
one reason for the low number of studies on choline intake. This calls for action for extended 214 
analysis of choline contents in foods.  215 
Indeed, few studies have analyzed the intakes of individual choline forms in relation to CVD. 216 
Zheng et al. [27] reported a higher PC intake to be associated with increased risk of all-cause 217 
and CVD mortality among healthy American men and women, in particular among diabetic 218 
patients. As in our study, PC was the major source of dietary choline. However, the authors did 219 
not observe an association between PC intake and incident CVD and suggested that the effects 220 
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of PC intake may be stronger on CVD prognosis than on CVD development. A Japanese 221 
population-based cohort study [28] found a positive association of SM, but not PC or total 222 
choline with cardiovascular mortality risk in healthy men. In animal studies, feeding SM to 223 
either LDLr KO mice [29] or apoE-/- mice [30] gave contradicting results on atherogenesis. 224 
Indeed, our finding of an increase in AMI risk with increasing SM intake is consistent with the 225 
findings of Nagata et al. [28], despite differences in choline sources in a typical Japanese diet 226 
compared to a Nordic diet [6]. 227 
4.2 Possible mechanisms 228 
The underlying mechanisms for potential associations between dietary choline and AMI 229 
incidence remain elusive. Digestion of both PC and SM is thought to impair intestinal 230 
cholesterol absorption [3,31], thus affecting lipid metabolism. In clinical studies, PC and SM 231 
from eggs is associated with beneficial changes in biomarkers related to reverse cholesterol 232 
transport and high-density lipoprotein characteristics [31,32], suggesting a favorable rather than 233 
a negative effect on atherosclerosis. At the same time, dietary choline, and choline-containing 234 
compounds such as PC, may exert negative effects through the conversion to trimethylamine 235 
by the intestinal microbiota, which is absorbed and transformed in the liver to TMAO by flavin-236 
containing monooxygenase 3 (FMO3) [33]. Several studies, both in animals and humans, 237 
reported an association between dietary choline and TMAO formation, as well as a strong 238 
positive correlation between plasma TMAO concentration and cardiovascular events [33–36]. 239 
Indeed, we also observed increased TMAO levels at higher choline intakes, which may explain 240 
the association with increased CVD risk at least partly. Plasma TMAO might advance 241 
atherosclerosis by reduction of reverse cholesterol transport, increased macrophage cholesterol 242 
accumulation, upregulation of macrophage scavenger receptors and augmented foam cell 243 
formation, resulting in increased inflammation and low-density lipoprotein cholesterol 244 
oxidation [37,38]. A clear mechanistic link between circulating TMAO and CVD is, however, 245 
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not yet validated. Additionally, circulating TMAO is not only influenced by diet, but also by 246 
the gut microbiome, FMO3 activity and excretion capacity [33,36], factors which were outside 247 
the scope of this study. Whether TMAO is a real contributor to atherosclerosis development or 248 
merely a marker of underlying pathogenic factors remains requires further research. 249 
Second, PC is crucial for the formation of VLDL and its secretion from the liver [39]. The major 250 
fate of choline is conversion to PC and an estimated 70% of hepatic PC is made via the Kennedy 251 
pathway [2], however, to the best of our knowledge, there is no data on the amount of dietary 252 
choline incorporated into VLDL phospholipids. PC and other phospholipids produced in the 253 
Kennedy pathway may influence lipid metabolism through activation of peroxisome 254 
proliferator-activated receptor alpha [40]. In the current study, we found no baseline 255 
associations between choline intake and serum lipid parameters, nor did adjusting for such 256 
parameters alter the risk association between choline intake and later AMI. However, any 257 
association between dietary choline and serum lipid parameters in our cohort might have been 258 
masked by high prevalence of statin use, although we did not find any interaction according to 259 
statin treatment in subgroup analyses. Nevertheless, our results deem it less likely that the 260 
choline-AMI risk relationship is explained by altered lipid levels per se. 261 
Dietary choline intake was inversely associated with plasma tHcy concentrations in our cohort, 262 
being in line with several intervention studies showing that choline supplementation lowers 263 
plasma tHcy concentrations [41–44]. However, the causality of the association between 264 
homocysteine and AMI has been questioned and lowering of tHcy concentrations was not 265 
associated with reduced incidence of cardiovascular events in a meta-analysis of 8 randomized 266 
trials including 37 485 participants [45]. 267 
Also, dietary choline intake has been associated with lower inflammation markers such as CRP, 268 
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) in a cross sectional study 269 
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involving healthy participants [46]. Pre-clinical studies showed potential anti-inflammatory 270 
effects of sphingolipids (with SM as main contributor) but the limited number of human studies 271 
and the use of complex phospholipid mixtures instead of single phospholipids, make it difficult 272 
to conclude on the effects of sphingolipids on inflammation [47]. In the present study, we did 273 
not observe any association between dietary choline and CRP. Il-6, TNF-α and neopterin were 274 
not investigated in our study. 275 
The reported median energy-adjusted total choline intake was lower than the recommended 276 
intake [4,10]. This is in accordance with observational data from European [48,49], North-277 
American [27,42,50,51] and Norwegian populations [13,17]. Since high choline intake was 278 
associated with AMI risk observed in this study and low choline intake has been associated 279 
with other adverse health outcomes, such as cancer, neurodegenerative diseases[4,9] and low 280 
bone mineral density [17], more research on health effects of choline intake is needed to define 281 
an adequate intake. The lack of correlation between dietary and plasma choline and a validated 282 
biomarker for choline intake [6,13,17], complicates this determination even more. 283 
Increased PC and SM intake was associated with augmented AMI risk in our population. These 284 
fat soluble choline forms are mainly found in products of animal origin like eggs, beef, chicken, 285 
fish and milk [4]. Milk, meat and fish consumption increased gradually over the quartiles, while 286 
egg consumption in the highest quartile of total choline intake was 2.4 times higher compared 287 
to the lowest. Notably, these choline sources tend to have high cholesterol content (especially 288 
eggs) [11] and intake should be limited according to current dietary guidelines in context of 289 
general and cardiovascular health [11,52]. Additionally, eggs, processed and unprocessed meat 290 
are also high in carnitine, a TMAO precursor, and sodium (processed meat) which are 291 
associated with CVD risk via different pathways [53]. In contrast, a higher total choline intake 292 
was associated with higher vegetable and fibre intake, which are inversely associated with CVD 293 
risk [11]. Increased ingestion of plant-based food items result in increased intake of water-294 
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soluble choline forms, which were not associated AMI risk in our study. Thus, a high intake of 295 
the fat-soluble choline forms may be a marker of an otherwise unhealthy diet and therefore be 296 
associated with AMI risk. Importantly, findings for a nutrient are not necessarily valid for a 297 
food item containing that nutrient.  298 
Even the association between eggs, which contain a high amount of PC and SM, and CVD 299 
remains controversial [53–55]. Further research is needed to explore the underlying 300 
mechanisms for the association between fat-soluble choline forms, the food items contributing 301 
to their intake and CVD risk. 302 
4.3 Strengths and limitations 303 
Among the strengths of the current study are the large sample size, the prospective design and 304 
the long-term follow-up. Detailed clinical and metabolic characterization of the population was 305 
available, and dietary intake of all choline forms and plasma concentration of choline were 306 
estimated. Additionally, the dietary analyses were adjusted for reported energy intake, which 307 
improves the accuracy of the estimates.  308 
Secondly, to the best of our knowledge, choline data in foods are only presented by the USDA 309 
database [5]. There is no data on choline content of Norwegian food items and there are 310 
difficulties in replacing local foods with foods included in the database that makes it impossible 311 
to exclude discrepancies. Next, the used FFQ was not validated for choline intake [56] and only 312 
filled out at baseline which makes it impossible to detect dietary changes over time. 313 
Additionally, random measurement error in estimated choline intake may have led to regression 314 
dilution bias and attenuated the relationship between choline intake and AMI. The ability to 315 
establish causality from this data is limited since it is impossible to exclude residual 316 
confounding.  317 
4.4 Conclusion 318 
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In conclusion, increased intakes of total choline and choline forms PC and SM were associated 319 
with higher long-term AMI risk in patients with SAP. This is an important finding in light of 320 
the lower than recommended average intake in this cohort, and the widespread use of choline 321 
supplements. Therefore, future studies are warranted to explore underlying mechanisms for this 322 
association, as well as for improving dietary guidelines.323 
1 
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